About this Research Topic
Today, our understanding of chronic myeloid leukemia (CML) dramatically benefits from the burgeoning field of biomedical technologies and pioneering research towards novel biomarkers detection. The state of the art is rapidly evolving, with an increased interest in uncovering new biomarkers that might be also targetable in order to mitigate possible chemotherapy-associated side-effects and to eradicate the chronicity of the disease. Such new markers, including for example IL6R and MYC, particularly interesting in patients resistant to conventional treatment, along with several dysregulated miRNAs such as miR-451 and miR-21, closely associated with the progression of disease, and response to therapeutics, represent promising avenues of investigation. These fields of research, i.e., the discovery of drug resistance mechanisms, including the strategies on how to overcome therapy resistance, and the liquid biopsy, which already is the gold standard for monitoring the disease progression and treatment response, are currently at the pinnacle of scientific research interests on CML.
Moreover, cutting-edge, non-invasive detection methods and the exploration of novel biomarkers like miRNAs pave the way towards innovative diagnostic and therapeutic modalities, making this a particularly worthwhile area of exploration for the scientific community. Another particular area that holds significant promise is the integration of genetic and epigenetic factors towards gene expression-based biomarkers. This innovative approach, addressed in several innovative studies, has the potential to revolutionize prognosis and risk assessment by personalizing treatment regimens based on a patient’s unique genomic profile. Furthermore, these approaches will hopefully open an era towards the study of all the biomarkers and features that are independent of BCR/Abl, the driver oncogene of the disease.
While these advancements are promising, the field remains rife with many unanswered questions. Can we further improve the specificity and sensitivity of these biomarkers? What new detection technologies can we harness to potentiate our understanding of CML and guide more effective, targeted interventions to finally eradicate the disease?
With the present Research Topic, we welcome different article types including Original Articles, Mini-Reviews, Brief Research Reports, and Perspectives, focused on the themes outlined above. We aim to collect all the new studies spanning from molecular insights to clinical translatability, with the goal of advancing our understanding of CML and exploring alternative and innovative strategies for treating the disease and mitigating its pathological effects.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Moreover, cutting-edge, non-invasive detection methods and the exploration of novel biomarkers like miRNAs pave the way towards innovative diagnostic and therapeutic modalities, making this a particularly worthwhile area of exploration for the scientific community. Another particular area that holds significant promise is the integration of genetic and epigenetic factors towards gene expression-based biomarkers. This innovative approach, addressed in several innovative studies, has the potential to revolutionize prognosis and risk assessment by personalizing treatment regimens based on a patient’s unique genomic profile. Furthermore, these approaches will hopefully open an era towards the study of all the biomarkers and features that are independent of BCR/Abl, the driver oncogene of the disease.
While these advancements are promising, the field remains rife with many unanswered questions. Can we further improve the specificity and sensitivity of these biomarkers? What new detection technologies can we harness to potentiate our understanding of CML and guide more effective, targeted interventions to finally eradicate the disease?
With the present Research Topic, we welcome different article types including Original Articles, Mini-Reviews, Brief Research Reports, and Perspectives, focused on the themes outlined above. We aim to collect all the new studies spanning from molecular insights to clinical translatability, with the goal of advancing our understanding of CML and exploring alternative and innovative strategies for treating the disease and mitigating its pathological effects.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: biomarkers, CML, leukemia, detection, therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
